BACKGROUND: Hurthle cell carcinoma represents approximately 3% of all differentiated thyroid cancers. The terminology is often confusing, and discrimination between Hurthle cell carcinoma and benign Hurthle cell tumors can be unclear. Thus, optimal treatment of patients with these diseases remains unsettled. METHODS: The authors reviewed published evidence on the presentation, biologic behavior, and treatment outcomes for this disease. In addition, they summarized their experience involving a series of 14 patients with Hurthle cell carcinoma. RESULTS: Hurthle cell carcinoma generally produces thyroglobulin and rarely takes up radioactive iodine. It is frequently bilateral or multifocal within the thyroid gland and often presents with local invasion. Hurthle cell carcinoma is associated with a high rate of locoregional recurrence and significant mortality. CONCLUSIONS: The authors advocate total thyroidectomy with central neck dissection as the therapy of choice for patients with Hurthle cell carcinoma.
BACKGROUND:Hurthle cell carcinoma represents approximately 3% of all differentiated thyroid cancers. The terminology is often confusing, and discrimination between Hurthle cell carcinoma and benign Hurthle cell tumors can be unclear. Thus, optimal treatment of patients with these diseases remains unsettled. METHODS: The authors reviewed published evidence on the presentation, biologic behavior, and treatment outcomes for this disease. In addition, they summarized their experience involving a series of 14 patients with Hurthle cell carcinoma. RESULTS:Hurthle cell carcinoma generally produces thyroglobulin and rarely takes up radioactive iodine. It is frequently bilateral or multifocal within the thyroid gland and often presents with local invasion. Hurthle cell carcinoma is associated with a high rate of locoregional recurrence and significant mortality. CONCLUSIONS: The authors advocate total thyroidectomy with central neck dissection as the therapy of choice for patients with Hurthle cell carcinoma.
Authors: Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan Journal: J Clin Endocrinol Metab Date: 2013-03-29 Impact factor: 5.958
Authors: Yiyu Dong; Yongxing Gong; Fengshen Kuo; Vladimir Makarov; Ed Reznik; Gouri J Nanjangud; Omer Aras; Huiyong Zhao; Rui Qu; James A Fagin; Eric J Sherman; Bin Xu; Ronald Ghossein; Timothy A Chan; Ian Ganly Journal: Mol Cancer Ther Date: 2021-11-17 Impact factor: 6.009
Authors: Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa Journal: Langenbecks Arch Surg Date: 2014-02 Impact factor: 3.445
Authors: Ian Ganly; Vladimir Makarov; Shyamprasad Deraje; YiYu Dong; Ed Reznik; Venkatraman Seshan; Gouri Nanjangud; Stephanie Eng; Promita Bose; Fengshen Kuo; Luc G T Morris; Inigo Landa; Pedro Blecua Carrillo Albornoz; Nadeem Riaz; Yuri E Nikiforov; Kepal Patel; Christopher Umbricht; Martha Zeiger; Electron Kebebew; Eric Sherman; Ronald Ghossein; James A Fagin; Timothy A Chan Journal: Cancer Cell Date: 2018-08-13 Impact factor: 31.743